Mucosal Unadjuvanted Booster Vaccines Elicit Local IgA Responses by Conversion of Pre-Existing Immunity in Mice
- A nasal vaccine could be more effective and tolerable for children and adults afraid of needles.
- Participants who received the highest dose of CVXGA showed significantly lower rates of symptomatic COVID-19 infection.
- The vaccine produced a mucosal antibody response rate of 51.9% in higher dose groups, compared to 21.4% in lower dose groups.
- Based on phase 1 trial data, two larger clinical studies are currently underway.
31 Articles
31 Articles
Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice
Mucosal delivery of vaccine boosters induces robust local protective immune responses even without any adjuvants. Yet, the mechanisms by which antigen alone induces mucosal immunity in the respiratory tract remain unclear. Here we show that an intranasal booster with an unadjuvanted recombinant SARS-CoV-2 spike protein, after intramuscular immunization with 1 μg of mRNA–LNP vaccine encoding the full-length SARS-CoV-2 spike protein (Pfizer/BioNTe…

Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial
CINCINNATI, July 4, 2025 /PRNewswire/ -- During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus invading the nasal tissues of its victims, then causing millions of deaths by spreading through the body…
Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial - PressReach
CINCINNATI, July 4, 2025 /PRNewswire/ — During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus invading the nasal tissues of its victims, then causing millions of deaths by spreading through the body and robbing the sickest people of their ability to breathe. While the traditional way to administer protection has been to inject vaccines into the bloodstream, many experts called for…
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium